Curis to Present at the 6th Annual OMI Summit on Hematologic Malignancies
LEXINGTON, Mass., March 15, 2019 -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that Dr. Robert E. Martell, Head of Research & Development, will present a pipeline update at Oncology Meeting Innovation’s (OMI’s) 6th Annual Summit on Hematologic Malignancies on Saturday, March 16th, 11:10 a.m. PDT at the Fairmont Château in Whistler, British Columbia, Canada.
The slides of the presentation will be available on the Company's website: www.curis.com on the same day at 9:00 am EDT.
About Curis, Inc.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.
For More Information: